Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a protein receptor on T immune cells that prevents the cells from killing other cells, such as cancer cells. Blocking CTLA-4 with a specific antibody is an ...
TAMPA, Fla. — Checkpoint inhibitors that activate the immune system to target cancer cells for destruction have revolutionized the treatment landscape for patients with advanced melanoma, leading to ...
AUSTIN, Texas, March 09, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Researchers at Salk Institute for Biological Studies ...
A novel immunotherapy combination is proving to be both safe and manageable for patients with prostate cancer, according to updated Phase 1 trial data presented at the 2026 ASCO Genitourinary Cancers ...
Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results